One case report and literature review about pure red cell aplasia following renal transplantation
Objective To report one case of pure red cell aplasia(PRCA) following renal transplantation,and to systematically review pathology,clinical manifestation,diagnosis and differential diagnosis and treatment principle of PRCA in order to improve the understanding of the disease.Methods A 46 years old m...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Department of Journal of Clinical Nephrology
2015-01-01
|
| Series: | Linchuang shenzangbing zazhi |
| Subjects: | |
| Online Access: | http://www.lcszb.com/thesisDetails?columnId=57921527&Fpath=home&index=0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Objective To report one case of pure red cell aplasia(PRCA) following renal transplantation,and to systematically review pathology,clinical manifestation,diagnosis and differential diagnosis and treatment principle of PRCA in order to improve the understanding of the disease.Methods A 46 years old male patient presented hemoglobin progressive decline after renal transplantation,and blood transfusion and EPO supplementation could not improve the symptom.The bone marrow examination revealed the diagnosis of PRCA.According to the above clinical data we summarized literatures.Results The patient got a stable state through the symptomatic treatment.Literature review showed that PRCA may be caused due to immunosuppression and intercurrent infection after the application of solid organ transplantation.After adjustment of drugs,and administration of IVIG,etc.,patients always obtain a good prognosis.Conclusions For patients undergoing solid organ transplantation who once presented unexplained hemoglobin decline,PRCA should be immediately suspected,and red blood cells are counted and bone marrow examination is carried out at the same time.The red blood cell transfusion support can be selected in emergency condition.Other treatment includes adjustment of the EPO preparation type,avoidance of application of immune inhibitor which can cause anemia,and intravenous immunoglobulin. |
|---|---|
| ISSN: | 1671-2390 |